

DAFTAR PUSTAKA

- Adham, M. *et al.* (2013a) 'Epstein-barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment', *Clinical Cancer Research*, 19(8), pp. 2175–2186. doi: 10.1158/1078-0432.CCR-12-2897.
- Adham, M. *et al.* (2013b) 'Epstein-barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment', *Clinical Cancer Research*, 19(8), pp. 2175–2186. doi: 10.1158/1078-0432.CCR-12-2897.
- Anandharaj, A. *et al.* (2016) 'EBV and not HPV sensitizes tobacco-associated head and neck cancer cell line FaDu to radiotherapy', *Acta Oto-Laryngologica*, 136(4), pp. 354–362. doi: 10.3109/00016489.2015.1114182.
- Bagan, L. *et al.* (2016a) 'Prevalence of salivary Epstein-Barr virus in potentially malignant oral disorders and oral squamous cell carcinoma', *Medicina Oral Patologia Oral y Cirugia Bucal*, 21(2), pp. e157–e160. doi: 10.4317/medoral.20785.
- Bagan, L. *et al.* (2016b) 'Prevalence of salivary Epstein-Barr virus in potentially malignant oral disorders and oral squamous cell carcinoma', *Medicina Oral Patologia Oral y Cirugia Bucal*, 21(2), pp. e157–e160. doi: 10.4317/medoral.20785.
- Baskar, R. *et al.* (2012) 'Cancer and radiation therapy: Current advances and future directions', *International Journal of Medical Sciences*, 9(3), pp. 193–199. doi: 10.7150/ijms.3635.
- Bourhis, J. *et al.* (2006) 'Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis', *Lancet*, 368(9538), pp. 843–854. doi: 10.1016/S0140-6736(06)69121-6.
- Brana, I. and Siu, L. L. (2012) 'Locally advanced head and neck squamous cell cancer: Treatment choice based on risk factors and optimizing drug prescription', *Annals of Oncology*. Elsevier Masson SAS, 23(SUPPL. 10), pp. x178–x185. doi: 10.1093/annonc/mds322.
- Chu, H. W. *et al.* (2019) 'Identification of salivary biomarkers for oral cancer detection with untargeted and targeted quantitative proteomics approaches', *Molecular Cellular Proteomics*, 18(9), pp. 1796–1806. doi: 10.1074/mcp.RA119.001530.
- Draborg, A. H., Duus, K. and Houen, G. (2012) 'Epstein-barr virus and systemic lupus erythematosus', *Clinical and Developmental Immunology*, 2012(April 2015). doi: 10.1155/2012/370516.
- Dunmire, S. K., Verghese, P. S. and Balfour, H. H. (2018) 'Primary Epstein-Barr virus infection', *Journal of Clinical Virology*. Elsevier, 102(January), pp. 84–92. doi: 10.1016/j.jcv.2018.03.001.
- Fernandes, Q. *et al.* (2018) 'Role of Epstein-Barr virus in the pathogenesis of head and neck cancers and its potential as an immunotherapeutic target', *Frontiers in Oncology*, 8(JUL), pp. 1–14. doi: 10.3389/fonc.2018.00257.
- Gequelin, L. C. F. *et al.* (2011) 'Epstein-Barr virus: general factors, virus related diseases and measurement of viral load after transplant', *Mucocutaneous Manifestations of Viral Diseases*, 33(5), pp. 145–172. doi: 10.5581/1516-8484.20110103.
- Gibson, U. E. M., Heid, C. A. and Williams, P. M. (2011) 'A novel method for real time quantitative RT-PCR', *Genome Research*, 6(10), pp. 995–1001. doi: 10.1101/gr.6.10.995.

- Halili, M. R. *et al.* (2012) 'Epstein- barr virus (EBV) antibody in patients treated by radical radiotherapy for head and neck cancer', *Journal of Surgical Oncology*, 10(5), pp. 457–463. doi: 10.1002/jso.2930100511.
- Hallqvist, A. *et al.* (2011) 'Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group', *Lung Cancer*. Elsevier Ireland Ltd, 71(2), pp. 166–172. doi: 10.1016/j.lungcan.2010.05.011.
- Hou, X. *et al.* (2011) 'Different Clinical Significance of Pre- and Post-treatment Plasma Epstein-Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy', *Clinical Oncology*, 23(2), pp. 128–133. doi: 10.1016/j.clon.2010.09.001.
- Jha, H. C., Pei, Y. and Robertson, E. S. (2016) 'Epstein-barr virus: Diseases linked to infection and transformation', *Frontiers in Microbiology*, 7(OCT), pp. 1–16. doi: 10.3389/fmicb.2016.01602.
- Khademi, B. *et al.* (2010) 'Molecular diagnosis of nasopharyngeal carcinoma using detection of Epstein-Barr virus latent membrane protein-1 gene in cervical metastatic lymph nodes', *American Journal of Otolaryngology - Head and Neck Medicine and Surgery*. Elsevier B.V., 30(2), pp. 95–100. doi: 10.1016/j.amjoto.2008.02.013.
- Kim, K. Y. *et al.* (2017) 'Current state of PCR-based Epstein-barr virus DNA testing for nasopharyngeal cancer', *Journal of the National Cancer Institute*, 109(4), pp. 1–7. doi: 10.1093/jnci/djx007.
- Kiprian, D. *et al.* (2018) 'Human cytomegalovirus and Epstein-Barr virus infections increase the risk of death in patients with head and neck cancers receiving radiotherapy or radiochemotherapy', *Medicine (United States)*, 97(51), pp. 5–8. doi: 10.1097/MD.00000000000013777.
- Liang, S. B. *et al.* (2019) 'Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma', *Radiotherapy and Oncology*, 132, pp. 223–229. doi: 10.1016/j.radonc.2018.10.010.
- Luo, W. J. *et al.* (2019) 'Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification', *Oral Oncology*. Elsevier, 91(November 2018), pp. 7–12. doi: 10.1016/j.oraloncology.2019.01.012.
- Mo, Y., Wan, R. and Zhang, Q. (2016) 'Application of Reverse Transcription-PCR and Real-Time PCR in Nanotoxicity Research', 25(3), pp. 289–313. doi: 10.1016/j.bbi.2017.04.008.
- Muqmiroh, L. *et al.* (2018) 'The Radiation Dose Profile in Pediatric Interventional Cardiology to Estimate the Stochastic Effect Risk', *Journal of Vocational Health Studies*, 01(01), pp. 97–101. doi: 10.20473/jvhs.
- Nakanishi, Y. *et al.* (2017) 'Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma', *Cancer and Metastasis Reviews*. Cancer and Metastasis Reviews, 36(3), pp. 435–447. doi: 10.1007/s10555-017-9693-x.
- Peng, H. *et al.* (2016) 'Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy', *Scientific Reports*. Nature Publishing Group, 6(February), pp. 1–9. doi: 10.1038/srep22000.

- Pezzuto, F., Caponigro, F. and Lina, M. (2015) 'Update on Head and Neck Cancer : Current Knowledge on Epidemiology , Risk Factors , Molecular Features and Novel Therapies'. doi: 10.1159/000381717.
- Polz-Dacewicz, M. *et al.* (2016) 'Salivary and serum IL-10, TNF- α , TGF- β , VEGF levels in oropharyngeal squamous cell carcinoma and correlation with HPV and EBV infections', *Infectious Agents and Cancer*, 11(1), pp. 1–8. doi: 10.1186/s13027-016-0093-6.
- Pow, E. H. N. *et al.* (2011) 'Salivary Epstein-Barr virus DNA level in patients with nasopharyngeal carcinoma following radiotherapy', *Oral Oncology*. Elsevier Ltd, 47(9), pp. 879–882. doi: 10.1016/j.oraloncology.2011.06.507.
- Powles, T. *et al.* (2014) 'Head and neck cancer in patients with human immunodeficiency virus-1 infection: Incidence, outcome and association with Epstein-Barr virus', *Journal of Laryngology and Otology*, 118(3), pp. 207–212. doi: 10.1258/002221504322927982.
- Sher, D. J. *et al.* (2011) 'Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck', *International Journal of Radiation Oncology Biology Physics*, 80(5), pp. 1405–1411. doi: 10.1016/j.ijrobp.2010.04.029.
- Shuman, A. G. *et al.* (2012) 'Predictors of pain among patients with head and neck cancer', *Archives of Otolaryngology - Head and Neck Surgery*, 138(12), pp. 1147–1154. doi: 10.1001/jamaoto.2013.853.
- Slevin, F. *et al.* (2019) 'A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy \pm Chemotherapy', *Clinical Oncology*. Elsevier Ltd, 32(4), pp. 238–249. doi: 10.1016/j.clon.2019.11.009.
- Smatti, M. K. *et al.* (2017) 'Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar', *PLoS ONE*, 12(12), pp. 1–20. doi: 10.1371/journal.pone.0189033.
- Sophian, I. (2017) 'Prevalensi Komplikasi Mukosa Oral Akibat Radioterapi Pada Pasien Kanker Kepala Universitas Sumatera Utara'.
- Surjadi, N. and Amtha, R. (2013) 'Radiotherapy Reduced Salivary Flow Rate and Might Induced *C. albicans* Infection', *Journal of Dentistry Indonesia*, 19(1), pp. 1–6. doi: 10.14693/jdi.v19i1.124.
- To, E. W. H. *et al.* (2013) 'Rapid clearance of plasma epstein-barr virus DNA after surgical treatment of nasopharyngeal carcinoma', *Clinical Cancer Research*, 9(9), pp. 3254–3259.
- Wong, Y. F. *et al.* (2015) 'Treatment outcome for head and neck squamous cell carcinoma in a developing country: University Malaya Medical Centre, Malaysia from 2003-2010', *Asian Pacific Journal of Cancer Prevention*, 16(7), pp. 2903–2908. doi: 10.7314/APJCP.2015.16.7.2903.
- Yang, Q. *et al.* (2018) 'Concurrent chemoradiotherapy versus intensitymodulated radiotherapy alone for elderly nasopharyngeal carcinoma patients with pre-treatment Epstein-Barr virus DNA: A cohort study in an endemic area with long-term follow-up', *Journal of Cancer*, 9(17), pp. 3023–3031. doi: 10.7150/jca.26145.
- Zheng, X. H. *et al.* (2019) 'Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma', *Cancer Science*, 111(2), pp. 592–600. doi: 10.1111/cas.14281.